Your browser doesn't support javascript.
loading
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.
Janse van Rensburg, Helena J; Liu, Zhihui; Watson, Geoffrey A; Veitch, Zachary W; Shepshelovich, Daniel; Spreafico, Anna; Abdul Razak, Albiruni R; Bedard, Philippe L; Siu, Lillian L; Minasian, Lori; Hansen, Aaron R.
Afiliación
  • Janse van Rensburg HJ; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Liu Z; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Watson GA; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Veitch ZW; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Shepshelovich D; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Spreafico A; Medicine D, Tel-Aviv Medical Center and the Sackler School of Medicine, Tel Aviv, Israel.
  • Abdul Razak AR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Bedard PL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Minasian L; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Hansen AR; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Br J Cancer ; 129(4): 612-619, 2023 09.
Article en En | MEDLINE | ID: mdl-37419999
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans Idioma: En Revista: Br J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans Idioma: En Revista: Br J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Canadá